SecProbe.io

CORRESP
1
filename1.htm

Biodexa Pharmaceuticals PLC

1 Caspian Point

Caspian Way

Cardiff, CF10 4DQ

United Kingdom

March 20, 2024

VIA EDGAR

Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Christopher Edwards

     Re:
    Biodexa Pharmaceuticals PLC

    Registration Statement on Form F-1 (File No. 333-278040)

    Request for Acceleration of Effective Date

Ladies and Gentlemen:

Pursuant to Rule 461 of the
General Rules and Regulations under the Securities Act of 1933, as amended, Biodexa Pharmaceuticals PLC hereby respectfully requests that
the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form F-1 (the “Registration
Statement”) and declare the Registration Statement effective as of 5:00 p.m., Eastern Time, on March 27, 2024, or as soon as practicable
thereafter.

Please call Jason S. McCaffrey
of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 542-6000, with any comments or questions regarding
the Registration Statement.

    Very truly yours,

    BIODEXA PHARMACEUTICALS PLC

    By: /s/ Stephen Stamp

    Name: Stephen Stamp

    Title:   Chief Executive Officer & Chief Financial Officer

     cc:
    Jason S. McCaffrey, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.